Menu
Back to Journals » Lung Cancer: Targets and Therapy » Volume 15
Commentary
MARIPOSA: Can Amivantamab and Lazertinib Replace Osimertinib in the Front-Line Setting?
| Total article views | HTML views | PDF downloads | Totals | ||
|---|---|---|---|---|---|
| 1,540 | Dovepress* | 1,437+ | 25 | 1,462 | |
| PubMed Central* | 103 | 29 | 132 | ||
| Totals | 1,540 | 54 | 1,594 | ||
| *Since 12 April 2024 | |||||
View citations on PubMed Central and Google Scholar